Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Duhoux FP"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-19 z 19
    Tytuł:
    Breast Development and Cancer.
    Autorzy:
    Berliere M; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Gynecology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Duhoux FP; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    François A; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Pathology, King Albert II, Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Galant C; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Pathology, King Albert II, Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2023 Mar 13; Vol. 15 (6). Date of Electronic Publication: 2023 Mar 13.
    Typ publikacji:
    Editorial
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Effects of Hormones on Breast Development and Breast Cancer Risk in Transgender Women.
    Autorzy:
    Berliere M; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Gynecology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Coche M; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Gynecology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Lacroix C; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Gynecology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Riggi J; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Gynecology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Coyette M; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Plastic Surgery, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Coulie J; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Plastic Surgery, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Galant C; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Pathology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Fellah L; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Radiology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Leconte I; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Radiology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Maiter D; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Duhoux FP; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    François A; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.; Department of Pathology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, 1200 Brussels, Belgium.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2022 Dec 30; Vol. 15 (1). Date of Electronic Publication: 2022 Dec 30.
    Typ publikacji:
    Journal Article; Review
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Inhibition of Mitochondrial Redox Signaling with MitoQ Prevents Metastasis of Human Pancreatic Cancer in Mice.
    Autorzy:
    Capeloa T; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Van de Velde JA; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    d'Hose D; Biomedical Magnetic Resonance Unit, Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Lipari SG; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Derouane F; Pole of Medical Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Hamelin L; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Bedin M; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Vazeille T; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Duhoux FP; Pole of Medical Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Murphy MP; MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge CB2 0XY, UK.
    Porporato PE; Department of Molecular Biotechnology and Health Science, Molecular Biotechnology Center, University of Turin, 10126 Turin, Italy.
    Gallez B; Biomedical Magnetic Resonance Unit, Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Sonveaux P; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.; Walloon Excellence in Life Sciences and Biotechnology (WELBIO) Research Institute, 1300 Wavre, Belgium.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2022 Oct 07; Vol. 14 (19). Date of Electronic Publication: 2022 Oct 07.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine.
    Autorzy:
    Derouane F; Department of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.; Institut de Recherche Expérimentale et Clinique (IREC), Pole of Medical Imaging, Radiotherapy and Oncology (MIRO), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    van Marcke C; Department of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.; Institut de Recherche Expérimentale et Clinique (IREC), Pole of Medical Imaging, Radiotherapy and Oncology (MIRO), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Berlière M; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.; Department of Gynecology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.; Institut de Recherche Expérimentale et Clinique (IREC), Pole of Gynecology (GYNE), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Gerday A; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.; Department of Gynecology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.
    Fellah L; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.; Department of Radiology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.
    Leconte I; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.; Department of Radiology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.
    Van Bockstal MR; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.; Department of Pathology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.
    Galant C; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.; Department of Pathology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.
    Corbet C; Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology and Therapeutics (FATH), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Duhoux FP; Department of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.; Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.; Institut de Recherche Expérimentale et Clinique (IREC), Pole of Medical Imaging, Radiotherapy and Oncology (MIRO), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2022 Aug 11; Vol. 14 (16). Date of Electronic Publication: 2022 Aug 11.
    Typ publikacji:
    Journal Article; Review
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    MitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice.
    Autorzy:
    Capeloa T; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Krzystyniak J; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Rodriguez AC; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Payen VL; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Zampieri LX; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Pranzini E; Department of Experimental and Clinical Biomedical Sciences Mario Serio, University of Florence, 50134 Firenze, Italy.
    Derouane F; Pole of Medical Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Vazeille T; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Bouzin C; IREC Imaging Platform (2IP), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Duhoux FP; Pole of Medical Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Murphy MP; MRC Mitochondrial Biology Unit, Department of Medicine, University of Cambridge, Cambridge CB2 0XY, UK.
    Porporato PE; Department of Molecular Biotechnology and Health Science, Molecular Biotechnology Center, University of Turin, 10126 Turin, Italy.
    Sonveaux P; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2022 Mar 15; Vol. 14 (6). Date of Electronic Publication: 2022 Mar 15.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    BRCA1 Mutation: An Insidious Enemy with Multiple Facets….
    Autorzy:
    Godin P; King Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
    Duhoux FP; King Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
    Mazzeo F; King Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
    Rojas M; Breast Clinic, Department of Oncology Centre hospitalier de Mouscron CHM Mouscron, Mouscron, Belgium.
    Bollue E; Breast Clinic, Department of Gynaecology, Centre Hospitalier Namur-Mont Godinne, CHU Namur, Namur, Belgium.
    François A; King Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
    Galant C; King Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
    Coulie J; King Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
    Coyette M; King Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
    Lentini A; King Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
    Deswisen Y; King Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
    Perlepe V; King Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
    Fellah L; King Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
    Leconte I; King Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
    Berlière M; King Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
    Pokaż więcej
    Źródło:
    Case reports in oncology [Case Rep Oncol] 2022 Mar 14; Vol. 15 (1), pp. 238-244. Date of Electronic Publication: 2022 Mar 14 (Print Publication: 2022).
    Typ publikacji:
    Case Reports
    Raport
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer.
    Autorzy:
    Migeotte A; Université catholique de Louvain, Brussels, Belgium.; Department of Medical Oncology, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Brussels, Belgium.
    Dufour V; Université catholique de Louvain, Brussels, Belgium.; Department of Medical Oncology, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Brussels, Belgium.
    van Maanen A; Statistical support unit, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Brussels, Belgium.
    Berliere M; Department of Gynecology, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Brussels, Belgium.; Institut de Recherche Expérimentale et Clinique (Pôle GYNE), Université catholique de Louvain, Brussels, Belgium.
    Canon JL; Department of Oncology and Hematology, Grand Hôpital de Charleroi, Charleroi, Belgium.
    Taylor D; Department of Medical Oncology, CHU UCL Namur, site Sainte-Elisabeth, Namur, Belgium.
    Duhoux FP; Department of Medical Oncology, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Brussels, Belgium. francois.duhoux@uclouvain.be.; Institut de Recherche Expérimentale et Clinique (Pôle MIRO), Université catholique de Louvain, Brussels, Belgium. francois.duhoux@uclouvain.be.
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2021 Nov 11; Vol. 21 (1), pp. 1204. Date of Electronic Publication: 2021 Nov 11.
    Typ publikacji:
    Journal Article; Multicenter Study; Observational Study
    MeSH Terms:
    Ado-Trastuzumab Emtansine/*therapeutic use
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Breast Neoplasms/*drug therapy
    Ado-Trastuzumab Emtansine/pharmacology ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/antagonists & inhibitors ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/diagnosis ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Capecitabine/pharmacology ; Capecitabine/therapeutic use ; Female ; Follow-Up Studies ; Humans ; Lapatinib/pharmacology ; Lapatinib/therapeutic use ; Middle Aged ; Neoplasm Staging ; Progression-Free Survival ; Receptor, ErbB-2/analysis ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/metabolism ; Retrospective Studies
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study.
    Autorzy:
    van Marcke C; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.
    Honoré N; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.
    van der Elst A; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.
    Beyaert S; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.
    Derouane F; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.
    Dumont C; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.
    Aboubakar Nana F; Department of Pneumology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle PNEU), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
    Baurain JF; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.
    Borbath I; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.; Department of Hepatogastroenterology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Brussels, Belgium.
    Collard P; Department of Pneumology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle PNEU), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
    Cornélis F; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.
    De Cuyper A; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.
    Duhoux FP; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.
    Filleul B; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Department of Medical Oncology, Hôpital de Jolimont, Haine-Saint-Paul, Belgium.
    Galot R; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.
    Gizzi M; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Department of Medical Oncology, Grand Hôpital de Charleroi (GHdC), Charleroi, Belgium.
    Mazzeo F; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.
    Pieters T; Department of Pneumology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle PNEU), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
    Seront E; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Department of Medical Oncology, Hôpital de Jolimont, Haine-Saint-Paul, Belgium.
    Sinapi I; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Department of Medical Oncology, Grand Hôpital de Charleroi (GHdC), Charleroi, Belgium.
    Van den Eynde M; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.; Department of Hepatogastroenterology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Brussels, Belgium.
    Whenham N; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.; Department of Medical Oncology, Clinique Saint-Pierre, Ottignies, Belgium.
    Yombi JC; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium.; Department of General Internal Medicine, Cliniques universitaires Saint-Luc, Brussels, Belgium.
    Scohy A; Department of Microbiology, Cliniques universitaires Saint-Luc, Brussels, Belgium.
    van Maanen A; Statistics unit, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Brussels, Belgium.
    Machiels JP; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium. .; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200, Brussels, Belgium. .
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2021 May 20; Vol. 21 (1), pp. 578. Date of Electronic Publication: 2021 May 20.
    Typ publikacji:
    Journal Article; Observational Study
    MeSH Terms:
    COVID-19/*diagnosis
    COVID-19/*epidemiology
    Neoplasms/*therapy
    Aged ; Ambulatory Care/statistics & numerical data ; Belgium/epidemiology ; COVID-19/complications ; Cancer Care Facilities ; Cohort Studies ; Female ; Health Personnel/statistics & numerical data ; Humans ; Male ; Middle Aged ; Neoplasms/epidemiology ; Risk Factors ; SARS-CoV-2
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Tumor apelin and obesity are associated with reduced neoadjuvant chemotherapy response in a cohort of breast cancer patients.
    Autorzy:
    Gourgue F; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.; Metabolism and Nutrition Research Group, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life Sciences and BIOtechnology), UCLouvain, Université catholique de Louvain, Brussels, Belgium.
    Derouane F; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium.
    van Marcke C; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium.
    Villar E; Breast Clinic, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
    Dano H; Department of Pathology, Cliniques Universitaires St Luc, Brussels, Belgium.
    Desmet L; Statistical Methodology and Computing Service, LIDAM, Université Catholique de Louvain, Brussels, Belgium.
    Bouzin C; Imaging Platform 2IP, Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Université catholique de Louvain, Brussels, Belgium.
    Duhoux FP; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium. francois.duhoux@uclouvain.be.
    Cani PD; Metabolism and Nutrition Research Group, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life Sciences and BIOtechnology), UCLouvain, Université catholique de Louvain, Brussels, Belgium. .
    Jordan BF; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium. .
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2021 May 10; Vol. 11 (1), pp. 9922. Date of Electronic Publication: 2021 May 10.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Apelin/*metabolism
    Breast Neoplasms/*therapy
    Neoadjuvant Therapy/*statistics & numerical data
    Obesity/*epidemiology
    Adult ; Aged ; Apelin/analysis ; Body Mass Index ; Breast/pathology ; Breast/surgery ; Breast Neoplasms/complications ; Breast Neoplasms/epidemiology ; Breast Neoplasms/pathology ; Chemotherapy, Adjuvant/statistics & numerical data ; Female ; Humans ; Mastectomy ; Middle Aged ; Neoadjuvant Therapy/methods ; Obesity/complications ; Retrospective Studies ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Characterization of Preoperative, Postsurgical, Acute and Chronic Pain in High Risk Breast Cancer Patients.
    Autorzy:
    Forget P; Institute of Applied Health Sciences, Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK.; Department of Anaesthesia, NHS Grampian, Aberdeen AB25 2ZD, UK.
    Sitter TM; Institute of Applied Health Sciences, Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK.
    Hollick RJ; Institute of Applied Health Sciences, Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK.; Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen AB25 2ZD, UK.; MRC versus Arthritis Centre for Musculoskeletal Health and Work, Aberdeen AB25 2ZD, UK.
    Dixon D; Institute of Applied Health Sciences, Health Psychology, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK.
    van Maanen A; Biostatistics Unit, King Albert II Institute, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium.
    Dekleermaker A; Clinical Pharmacology Unit, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium.
    Duhoux FP; Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique (POLE MIRO), UCLouvain, 1200 Brussels, Belgium.
    De Kock M; Department of Anesthesiology, Centre Hospitalier Wallonie Picarde (CHWAPI), 7500 Tournai, Belgium.
    Berliere M; Department of Gynecology, Breast Clinic, King Albert II Institute, Cliniques universitaires Saint-Luc, UCLouvain, 1200 Brussels, Belgium.
    Pokaż więcej
    Corporate Authors:
    The KBCt Group
    Źródło:
    Journal of clinical medicine [J Clin Med] 2020 Nov 26; Vol. 9 (12). Date of Electronic Publication: 2020 Nov 26.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial.
    Autorzy:
    Forget P; Institute of Applied Health Sciences, Epidemiology group, School of Medicine, Medical Science and Nutrition, University of Aberdeen, Department of Anaesthesia, NHS Grampian, Aberdeen, United Kingdom.
    Bouche G; The Anticancer Fund, Brussels, Belgium.
    Duhoux FP; Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (POLE MIRO), UCLouvain, Brussels, Belgium.
    Coulie PG; de Duve Institute, UCLouvain, Brussels, Belgium.
    Decloedt J; Department of Oncology, St-Blasius Hospital, Dendermonde, Belgium.
    Dekleermaker A; Clinical Pharmacology Unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
    Guillaume JE; Department of Anesthesiology, Ste-Elisabeth hospital, Namur, Belgium.
    Ledent M; Department of Anesthesiology, St-Pierre Clinic, Ottignies, Belgium.
    Machiels JP; Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (POLE MIRO), UCLouvain, Brussels, Belgium.
    Mustin V; Department of Anesthesiology, St-Pierre Clinic, Ottignies, Belgium.
    Swinnen W; Department of Anesthesiology, St-Blasius Hospital, Dendermonde, Belgium.
    van Maanen A; Biostatistics Unit, King Albert II Institute, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
    Vander Essen L; Department of Anesthesiology, St-Pierre Clinic, Ottignies, Belgium.
    Verougstraete JC; Department of Gynecology, St-Pierre Clinic, Ottignies, Belgium.
    De Kock M; Department of Anesthesiology, Centre Hospitalier Wallonie Picarde (CHWAPI), Tournai, Belgium.
    Berliere M; Department of Gynecology, Breast Clinic, King Albert II Institute, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2019 Dec 04; Vol. 14 (12), pp. e0225748. Date of Electronic Publication: 2019 Dec 04 (Print Publication: 2019).
    Typ publikacji:
    Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Intraoperative Care*
    Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage
    Breast Neoplasms/*drug therapy
    Breast Neoplasms/*pathology
    Ketorolac/*administration & dosage
    Adult ; Aged ; Aged, 80 and over ; Belgium ; Breast Neoplasms/epidemiology ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Prospective Studies ; Recurrence ; Retrospective Studies ; Risk Assessment
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report.
    Autorzy:
    Baudon C; Oncology-Hematology Services, Grand Hôpital de Charleroi, 6000, Charleroi, Belgium. .; Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Université catholique de Louvain, 1200, Brussels, Belgium. .
    Duhoux FP; Oncology-Hematology Services, Grand Hôpital de Charleroi, 6000, Charleroi, Belgium.; Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Université catholique de Louvain, 1200, Brussels, Belgium.
    Sinapi I; Oncology-Hematology Services, Grand Hôpital de Charleroi, 6000, Charleroi, Belgium.
    Canon JL; Oncology-Hematology Services, Grand Hôpital de Charleroi, 6000, Charleroi, Belgium.
    Pokaż więcej
    Źródło:
    Journal of medical case reports [J Med Case Rep] 2016 Jun 16; Vol. 10, pp. 178. Date of Electronic Publication: 2016 Jun 16.
    Typ publikacji:
    Case Reports; Journal Article
    MeSH Terms:
    Antibodies, Monoclonal, Humanized/*adverse effects
    Antineoplastic Agents/*adverse effects
    Breast Neoplasms/*complications
    Breast Neoplasms/*drug therapy
    Trastuzumab/*adverse effects
    Tumor Lysis Syndrome/*complications
    Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Belgium ; Breast Neoplasms/pathology ; Fatal Outcome ; Female ; Humans ; Middle Aged
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.
    Autorzy:
    Laas E; Institut Curie, Department of Surgery, Paris, France.; Hopital Tenon, Department of Gynaecologic Surgery, Paris, France.
    Mallon P; Institut Curie, Department of Surgery, Paris, France.; Craigavon Area Hospital Breast Unit, Portadown Northern Ireland, BT63 5QQ.
    Duhoux FP; Institut Curie, Department of Medical Oncology, Paris, France.; Centre du Cancer, Cliniques universitaires Saint-Luc, Université catholique de Louvain, B-1200 Brussels, Belgium.
    Hamidouche A; Institut Curie, Department of Surgery, Paris, France.
    Rouzier R; Institut Curie, Department of Surgery, Paris, France.
    Reyal F; Institut Curie, Department of Surgery, Paris, France.; Hopital Tenon, Department of Gynaecologic Surgery, Paris, France.; Institut Curie, Department of Medical Oncology, Paris, France.; Centre du Cancer, Cliniques universitaires Saint-Luc, Université catholique de Louvain, B-1200 Brussels, Belgium.; Institut Curie, Translational Research Department, Residual Tumor and Response to Treatment, RT2Lab, Paris, France.; Institut Curie, UMR932, Immunity and Cancer, Paris, France.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2016 Feb 19; Vol. 11 (2), pp. e0148957. Date of Electronic Publication: 2016 Feb 19 (Print Publication: 2016).
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Gene Expression Regulation, Neoplastic*
    Transcriptome*
    Breast Neoplasms/*genetics
    Breast Neoplasms/*mortality
    Receptor, ErbB-2/*genetics
    Receptors, Estrogen/*genetics
    Breast Neoplasms/pathology ; Cluster Analysis ; Female ; Gene Expression Profiling ; Humans ; Kaplan-Meier Estimate ; Neoplasm Grading ; Neoplasm Metastasis ; Neoplasm Staging ; Prognosis ; Reproducibility of Results
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The place of extensive surgery in locoregional recurrence and limited metastatic disease of breast cancer: preliminary results.
    Autorzy:
    Berlière M; Breast Clinic, King Albert II Institute, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Duhoux FP; Breast Clinic, King Albert II Institute, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Taburiaux L; Breast Clinic, King Albert II Institute, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Lacroix V; Breast Clinic, King Albert II Institute, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Galant C; Breast Clinic, King Albert II Institute, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Leconte I; Breast Clinic, King Albert II Institute, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Fellah L; Breast Clinic, King Albert II Institute, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Lecouvet F; Breast Clinic, King Albert II Institute, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Bouziane D; Breast Clinic, King Albert II Institute, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Piette P; Breast Clinic, King Albert II Institute, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Lengele B; Breast Clinic, King Albert II Institute, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
    Pokaż więcej
    Źródło:
    BioMed research international [Biomed Res Int] 2015; Vol. 2015, pp. 782654. Date of Electronic Publication: 2015 Mar 18.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Breast Neoplasms/*surgery
    Liver Neoplasms/*surgery
    Neoplasm Recurrence, Local/*surgery
    Adult ; Aged ; Breast Neoplasms/pathology ; Disease-Free Survival ; Female ; Humans ; Liver Neoplasms/pathology ; Liver Neoplasms/secondary ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Prognosis
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Tamoxifen and ovarian function.
    Autorzy:
    Berliere M; Clinique du sein, Centre du Cancer, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium. />Duhoux FP
    Dalenc F
    Baurain JF
    Dellevigne L
    Galant C
    Van Maanen A
    Piette P
    Machiels JP
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2013 Jun 28; Vol. 8 (6), pp. e66616. Date of Electronic Publication: 2013 Jun 28 (Print Publication: 2013).
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Antineoplastic Agents, Hormonal/*therapeutic use
    Carcinoma, Ductal, Breast/*drug therapy
    Ovary/*physiopathology
    Tamoxifen/*therapeutic use
    Adult ; Amenorrhea/chemically induced ; Antineoplastic Agents, Hormonal/adverse effects ; Breast Neoplasms/blood ; Breast Neoplasms/drug therapy ; Breast Neoplasms/mortality ; Carcinoma, Ductal, Breast/blood ; Carcinoma, Ductal, Breast/mortality ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Estradiol/blood ; Female ; Humans ; Menstrual Cycle/drug effects ; Middle Aged ; Ovary/drug effects ; Premenopause ; Retrospective Studies ; Tamoxifen/adverse effects ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Antivascular therapy for epithelial ovarian cancer.
    Autorzy:
    Duhoux FP; Centre du Cancer, Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 1200 Brussels, Belgium.
    Machiels JP
    Pokaż więcej
    Źródło:
    Journal of oncology [J Oncol] 2010; Vol. 2010, pp. 372547. Date of Electronic Publication: 2009 Dec 23.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-19 z 19

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies